Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Johnson and Johnson sees further growth in second quarter

Johnson and Johnson sees further growth in second quarter

20th July 2011

Johnson and Johnson has reported positive signs of business expansion in the second quarter of the 2011 financial year.

The company's sales total for the period came to $16.6 billion (10.3 billion pounds), an increase of 8.3 percent compared to last year, driven primarily by strong growth in its international operations.

Its medical devices and diagnostics division was a key contributor to its positive performance, with sales advancing by 7.2 percent thanks to contributions from Ethicon's surgical care products, DePuy's sports medicine and neurovascular business and the Diabetes Care range, among other factors.

Across the group as a whole, the successful launch of new pharmaceutical agents and regulatory approval of several key products were also achieved.

William Weldon, chairman and chief executive officer of Johnson and Johnson, said: "We continue to invest in building leadership positions and capabilities and our pending acquisition of Synthes demonstrates our ongoing commitment to serve patients while enhancing shareholder value."

The Synthes deal was announced in April 2011 and is valued at $21.3 billion, with the transaction set to close in the first half of 2012.ADNFCR-8000103-ID-800627734-ADNFCR

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.